TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline in Recovery Assessment Scale, Domains and Stages (RAS-DS) total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Validity of Clinical food frequency questionnaire (FFQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of FFQ clinical tool
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: postoperative Meperidine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: residual torsional deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement Motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin microbiome features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average of area under the time-corrected creatinine clearance curve (AUC1-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perioperative depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: need for unscheduled treatment adaptation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Respiratory Muscle Strength Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peripheral Muscle Strength Assessment: Hand Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dynamic Balance Assessment: Mini-Balance Evaluation Systems Test (Mini-BESTest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of intravenous rifabutin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of intravenous 25-O-deacetyl-rifabutin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Curve - infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TNF alfa level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time taken for the child to be sedated adequately to start MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken till waking up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps Muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of SYT-510
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) of SYT-510
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of FFOCT to standard histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stigma Reduction: Prejudice
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stigma Reduction: Stereotypes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stigma Reduction: Discrimination
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disordered eating symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Absence of residual fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dissociation
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in reaching distance under shoulder abduction load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biliopancreatic events (BPE)
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Efficacy for Ostomy Self-Management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Probability of Having Blood Transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of the DROM test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Removal Percent
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Scar Characteristic: Extensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity measure of Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle function measures of lumbopelvic muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of skin texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in body mass and body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement error of ankle mean Arterial Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants with a 3 fold increase in HIV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Improvement Score (TIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BrainHealth Index (BHI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Treatment Emergent AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants maintaining a preboost anti-CHIKV SNA titer ≥100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of vaccine boosted participants with composite booster response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Skeletal Muscle Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximal Strength (10-RM Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in fasting blood sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in serum triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reliability of soft tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of soft tissue composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of soft tissue elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients determined eligible who enroll in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Pulmonary Rehab sessions completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects experiencing acute cellular rejection (ACR) >ISHLT 2R
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects experiencing hemodynamic compromise (HDC) rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Overall hemostatic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and type of invasive procedures performed
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: hemangioblastomas' volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preferred walking speed after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT-RSA measured maximum total point of motion (MTPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Run time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Severe CRS
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinically significant findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine efficacy against HFMD caused by CA16 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralizing antibody levels against EV71
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Veteran adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Client satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical status assessed at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antibiotic prescription at Day 0
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Major recurrence, any stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Rate of detrusor muscle sampling at TURBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of single instillation intra-vesical chemotherapy (SI-IVC) instillation within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of documentation of resection completeness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of documentation of all tumour number, tumour size and tumour location in the operative record
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: First channel establishment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total cognition composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fluid composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Crystallized composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with pleuropulmonary ultrasound abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Solicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Female Participants With Pregnancy Events
Endpoint domain: Adverse events/effects
Primary endpoint: Energy intake from sweet tasting carbohydrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Excited Component of the Positive and Negative Syndrome Scale (PEC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of severe BPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with Hepatitis C screening positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with mild to moderate influenza disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants with Severe Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Objective tumor response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Movement Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations in Sitting Posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in intermediate lipid biomarkers of CVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in intermediate biomarkers of CVD: blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in anthropometric metrics: BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of rescue analgesia (Ibuprofen consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom Distress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insomnia assessed by Richards-Campbell Sleep Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Insomnia assessed by State-Trait Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in the children's anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in the children's severity of psychopathology and improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the child's anxiety life interference
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Completion rate of required touch points
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Drop Discomfort VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who undergo knee replacement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse perinatal outcome predicted by UA Doppler indices
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse perinatal outcome predicted by MCA Doppler indices
Endpoint domain: Adverse events/effects
Primary endpoint: Total plasma branched chain amino acid (BCAA) area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma BCAA time-to-peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma BCAA C(MAX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evidence of disease progression in hospitalised patients (moderate and severe cases)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary effect on functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Daily Cigarette Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to Substitute from Cigarettes to HTPs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma Nicotine Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LUS-consolidation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bypass occlusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Late lumen loss at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients with serious adverse events during pregnancy
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term major negative events
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term metabolic measurements- BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long-term metabolic measurements- Cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long-term metabolic measurements- Triglycerides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long-term metabolic measurements- HbA1C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long-term metabolic measurements- glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HER2-low prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients achieving complete metabolic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of MRD detection using ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of MRD detection using ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Omission of Axillary Dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of BEMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Concentration (Tmax) of BEMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum level of ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum level of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Echo intensity of the rectus femoris muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fertility Information Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fertility Attitude Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preconceptional Health Knowledge Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preconceptional Health Attitude Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: stem survival rate
Endpoint domain: Mortality/survival
Primary endpoint: SARS-CoV-2 neutralizing antibody tiers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant changes in clinical and laboratory evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: screening performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline in ADAS-Cog-14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Provoked inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Secondary hypersensitivity (surface area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conditioned pain modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cadence (steps per minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Canadian Measure of Occupational Performance (CMOP) - satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: First occurrence of RT-PCR-confirmed influenza Type A symptomatic disease
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment-emergent serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment emergent Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of arterial and venous thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of cardiac arrhythmia due to atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in the number of relapses of bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: EEG (Alpha, Beta, Theta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Primary Safety endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Efficacy endpoint
Endpoint domain: Physiological/clinical
Primary endpoint: Prevalence of platelet dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: modified Ashworth Scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone dimensional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rest-to-exercise pulmonary DTPA clearance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects achieving minimal improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity Difference (SPID) From Baseline to 2-Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity Difference (SPID) From Baseline to 24-Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and stress assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC0-24weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes